Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Novo Nordisk (NVO) stock is falling Friday morning after the pharmaceutical ... Shares of FedEx (FDX) are plummeting in after-hours trading. The shipping giant reported first quarter adjusted earnings ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Structure Therapeutics (NASDAQ:GPCR), and Terns Pharmaceuticals (NASDAQ:TERN), which are all developing oral pills as weight loss treatments, are trading higher Friday following disappointing results ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

This post was written by Melanie Riehl On today's episode of Asking for a Trend, Host Josh Lipton breaks down some of the biggest stories from the trading day ... that players like Eli Lilly (LLY) and ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $70 ...

Hims & Hers Health to offer compounded Wegovy for $99/month to eligible military, teachers, nurses, and first responders.

Senator Sanders (I-Vt.) says CEOs of generic drugmakers are willing to sell Novo Nordisk’s (NVO) blockbuster obesity medicine ...